In 2012, the multikinase inhibitor ponatinib (Iclusig®, Figure 2) received FDA approval as the third-generation ABL inhibitor for the treatment of patients with CML and Ph + ALL.12 This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.